Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVAL phase 3 trial of recombinant human alkaline phosphatase in sepsis-associated acute kidney injury
jRCT2031210141Phase 3Suspended
- Sponsor
- AM-Pharma
- Start
- Jun 2021
01
Overview
Phase 3, randomised, double-blind trial in sepsis-associated acute kidney injury (S-AKI) (2 arms), sponsored by AM-Pharma. Primary endpoint: 28-day all-cause mortality. Started Jun 2021; status: suspended.
02
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on jRCT2031210141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210141.